IMMUTEP LIMITED - AMERICAN DEPOSITARY SHARES

Immutep Quarterly Activities Report Q2 FY25

31 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Patient Enrolment Completed for EFTISARC-NEO Phase II Trial

22 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Patient Enrolment Completed for INSIGHT-003

06 Jan 2025 07:00:00 By Nasdaq GlobeNewswire

Immutep Announces Initial Safety Data from First-in-Human Phase I Trial Evaluating IMP761

17 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep and Monash University Announce First Publication Detailing How Human LAG-3 Binds to MHC Class II

16 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Reports Promising New Data in Head and Neck Cancer at ESMO Immuno-Oncology 2024

12 Dec 2024 07:15:00 By Nasdaq GlobeNewswire

Immutep Announces Initiation of TACTI-004 Phase III Trial in First Line Non-Small Cell Lung Cancer

10 Dec 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep’s Efti Shows Excellent Survival Data from INSIGHT-003 Trial in Non-Small Cell Lung Cancer

14 Nov 2024 07:15:00 By Nasdaq GlobeNewswire

Positive Data from Phase II Trial in Soft Tissue Sarcoma Presented at CTOS 2024 Annual Meeting

14 Nov 2024 07:00:01 By Nasdaq GlobeNewswire

Immutep Quarterly Activities Report Q1 FY25

29 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep to Present New Phase IIb Data in PD-L1 Negative (CPS <1) Head and Neck Cancer at ESMO Immuno-Oncology 2024

28 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Announces First-in-Human Phase I Study of IMP761 Progresses to Dose Escalation Portion of Trial

17 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep to Participate in the 2024 Maxim Healthcare Virtual Summit

10 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Completes Patient Enrolment in Randomised Phase II of AIPAC-003 Trial in Metastatic Breast Cancer

03 Oct 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Receives A$3.6 million R&D Tax Incentive from French Government

24 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

New Data to be Presented from EFTISARC-NEO Phase II Evaluating Novel Triple Combination including Immutep’s Efti in Soft Tissue Sarcoma

18 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep’s Efti in Combination with MSD’s KEYTRUDA® Leads to Positive Efficacy with Favourable Safety in First Line Head and Neck Cancer

16 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Announces Late-Breaking Abstract in Head & Neck Cancer Selected for Oral Presentation at ESMO Congress 2024

20 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep Announces First Participant Dosed in Phase I Study of IMP761, a First in Class Agonist LAG-3 Antibody

14 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Immutep to Participate in Upcoming Investor Conferences

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire